OTLK Outlook Therapeutics, Inc. Stock Quote

OTLK [NASD]

Index	-	P/E	-	EPS (ttm)	-0.32	Insider Own	12.80%	Shs Outstand	150.73M	Perf Week	-6.61%
Market Cap	402.03M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	97.57%	Shs Float	89.63M	Perf Month	-9.24%
Income	-40.50M	PEG	-	EPS next Q	-0.07	Inst Own	9.00%	Short Float	3.51%	Perf Quarter	-5.04%
Sales	-	P/S	-	EPS this Y	66.00%	Inst Trans	1.43%	Short Ratio	3.45	Perf Half Y	141.69%
Book/sh	0.14	P/B	16.14	EPS next Y	29.00%	ROA	-150.50%	Target Price	-	Perf Year	63.77%
Cash/sh	0.21	P/C	10.81	EPS next 5Y	-	ROE	-675.90%	52W Range	0.58 - 4.26	Perf YTD	73.85%
Dividend	-	P/FCF	-	EPS past 5Y	43.50%	ROI	-	52W High	-46.95%	Beta	0.70
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	-	Gross Margin	-	52W Low	289.66%	ATR	0.15
Employees	8	Current Ratio	1.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.03	Volatility	7.52% 6.58%
Optionable	No	Debt/Eq	0.55	EPS Q/Q	76.10%	Profit Margin	-	Rel Volume	0.69	Prev Close	2.41
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	911.15K	Price	2.26
Recom	2.00	SMA20	-6.63%	SMA50	-9.09%	SMA200	21.42%	Volume	630,027	Change	-6.22%

Sep-11-19

Initiated

Ladenburg Thalmann

Buy

May-16-19

Initiated

Oppenheimer

Outperform

$12

Apr-22-19

Initiated

Ascendiant Capital Markets

Buy

Jul-07-21 08:05AM	Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer GlobeNewswire +5.79%
Jul-02-21 05:04AM	Does Outlook Therapeutics (NASDAQ:OTLK) Have A Healthy Balance Sheet? Simply Wall St.
Jun-14-21 08:05AM	Outlook Therapeutics Announces Inclusion in the Russell 2000® Index GlobeNewswire
Jun-08-21 08:05AM	Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial GlobeNewswire
May-27-21 08:05AM	Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010 GlobeNewswire
May-18-21 06:15AM	How Many Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Do Institutions Own? Simply Wall St.
May-14-21 08:05AM	Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update GlobeNewswire +7.73%
May-12-21 08:05AM	Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021 GlobeNewswire
Mar-31-21 09:23AM	Outlook Therapeutics' Bevacizumab-vikg Shows Favorable Safety Profile In Retinal Disease Study Benzinga
08:05AM	Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Mar-23-21 04:49AM	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Is Expected To Breakeven In The Near Future Simply Wall St.
Mar-04-21 09:00AM	Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -9.95%
Feb-17-21 08:05AM	Outlook Therapeutics to Participate in Cantor Fitzgeralds Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021 GlobeNewswire -8.36%
Feb-16-21 08:05AM	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update GlobeNewswire +8.70%
Feb-11-21 08:05AM	Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA (bevacizumab-vikg) GlobeNewswire -6.16%
Feb-04-21 11:18AM	Outlook Therapeutics Raises $35M Via Equity To Support ONS-5010 US Application, Shares Spike Benzinga +21.77%
09:05AM	Outlook Therapeutics Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA (bevacizumab-vikg) Through Planned BLA Submission GlobeNewswire
Feb-02-21 04:05PM	Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal GlobeNewswire
Jan-28-21 11:59PM	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million GlobeNewswire
05:35PM	Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock GlobeNewswire
Jan-12-21 08:05AM	Leading Ophthalmology Organization Launches Podcast Video with Firas Rahhal, MD, to Explore the Genesis and Promise of Outlook Therapeutics ONS-5010/LYTENAVA (bevacizumab-vikg) GlobeNewswire
Jan-05-21 08:00AM	Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Dec-23-20 09:05AM	Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Dec-07-20 08:04PM	Is OTLK A Good Stock To Buy Now? Insider Monkey
Dec-01-20 08:05AM	Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
Nov-19-20 08:05AM	Outlook Therapeutics Announces Creation of Global Retina Advisory Council GlobeNewswire +8.11%
Nov-11-20 09:05AM	Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA GlobeNewswire +9.18%
Nov-05-20 08:05AM	Outlook Therapeutics Secures $10 Million in Additional Working Capital GlobeNewswire +5.05%
Nov-03-20 08:35AM	Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA (bevacizumab-vikg) GlobeNewswire
Oct-22-20 08:00AM	Outlook Therapeutics to Present at the Virtual Investor KOL Roundtable GlobeNewswire
Oct-13-20 08:05AM	Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Oct-12-20 03:30PM	These 2 Penny Stocks Could See Outsized Gains, Says Oppenheimer TipRanks +15.86%
Oct-07-20 08:05AM	Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital GlobeNewswire
Sep-30-20 08:05AM	Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration GlobeNewswire +7.95%
Sep-08-20 08:05AM	Outlook Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-26-20 02:52PM	When Can We Expect A Profit From Outlook Therapeutics, Inc. (NASDAQ:OTLK)? Simply Wall St. -36.33%
08:05AM	Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA (bevacizumab-vikg) from NORSE 1 GlobeNewswire
Aug-14-20 08:05AM	Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Jul-17-20 08:05AM	Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jul-07-20 08:05AM	Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Jun-25-20 09:43AM	Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7% Zacks
08:05AM	Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Jun-23-20 08:00AM	Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules GlobeNewswire -5.15%
Jun-17-20 08:05AM	Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire
Jun-11-20 08:05AM	Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire -13.44%
Jun-10-20 08:12PM	Is Outlook Therapeutics, Inc. (OTLK) A Good Stock To Buy? Insider Monkey
Jun-09-20 08:05AM	Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series GlobeNewswire -5.83%
Jun-03-20 08:05AM	Outlook Therapeutics Announces Closing of $16.0 Million Private Placement GlobeNewswire -10.08%
May-26-20 08:05AM	Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA (bevacizumab-vikg) GlobeNewswire +16.33%
May-20-20 08:39AM	Some Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) Estimates Simply Wall St.
May-15-20 08:00AM	Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update GlobeNewswire
Apr-21-20 08:05AM	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors GlobeNewswire -5.61%
Apr-16-20 09:16AM	Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6% Zacks +7.00%
Apr-15-20 08:35AM	Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit GlobeNewswire +7.58%
Apr-14-20 08:05AM	Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2 GlobeNewswire
Mar-19-20 09:32AM	Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98% Simply Wall St. +5.88%
Mar-05-20 08:00AM	Outlook Therapeutics Announces LYTENAVA (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved GlobeNewswire
Feb-26-20 02:26PM	Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market GlobeNewswire -5.45%
Feb-25-20 09:15AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK ACCESSWIRE -8.32%
Feb-24-20 08:00AM	Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market GlobeNewswire -5.61%
Feb-18-20 01:28PM	INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims. GlobeNewswire +6.38%
Feb-14-20 08:00AM	Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020 GlobeNewswire -6.00%
Feb-04-20 08:00AM	Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire
Jan-28-20 08:00AM	Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 GlobeNewswire
Dec-26-19 08:00AM	Outlook Therapeutics Announces Completion of Warrant Restructuring GlobeNewswire
Dec-24-19 07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga -5.24%
Dec-23-19 09:00AM	Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions GlobeNewswire -49.57%
Dec-19-19 08:00AM	Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019 GlobeNewswire
Dec-03-19 08:00AM	Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010 GlobeNewswire +53.12%
Nov-13-19 10:44AM	What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)? Simply Wall St. -7.64%
Sep-11-19 08:00AM	Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire +16.64%
Aug-27-19 08:00AM	Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference GlobeNewswire -7.04%
Aug-20-19 08:00AM	Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD GlobeNewswire
Aug-14-19 04:15PM	Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019 GlobeNewswire
Jul-19-19 12:39PM	A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019 Benzinga -6.84%
Jul-18-19 12:05PM	A Look At Benzinga Pro's Most-Searched Tickers For July 18, 2019 Benzinga +34.87%
Jul-16-19 08:00AM	Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD GlobeNewswire
Jun-03-19 08:57AM	Hottest Wall Street Stories: What's Up, What's Down Zacks +7.50%
08:00AM	Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010 GlobeNewswire
May-24-19 12:50PM	A Look At Benzinga Pro's Most-Searched Tickers For May 24 Benzinga +42.35%
May-20-19 09:02AM	Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days MarketWatch +42.86%
May-17-19 03:17PM	Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know Benzinga +37.25%
09:47AM	Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days MarketWatch
May-16-19 09:48AM	Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer MarketWatch +68.06%
May-15-19 08:00AM	Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019 GlobeNewswire -11.62%
Apr-26-19 08:00AM	Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development GlobeNewswire +6.82%
Apr-10-19 09:00AM	Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -45.08%
Apr-01-19 08:00AM	Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010 GlobeNewswire
Mar-15-19 09:00AM	Outlook Therapeutics Announces Reverse Stock Split GlobeNewswire
Mar-05-19 08:00AM	Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements GlobeNewswire -6.49%
Mar-01-19 08:00AM	Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA GlobeNewswire
Feb-14-19 08:00AM	Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019 GlobeNewswire +24.27%
Feb-13-19 11:45AM	Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-01-19 09:15AM	Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement GlobeNewswire
Jan-22-19 09:00AM	Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants GlobeNewswire
Jan-02-19 09:15AM	Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement GlobeNewswire +10.00%
Dec-18-18 09:00AM	Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 GlobeNewswire +14.29%

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KENYON LAWRENCE A	CEO, Pres, CFO, Treas & Secy	Apr 20	Buy	1.83	10,000	18,300	18,926	Apr 20 07:54 PM
Haddadin Yezan Munther	Director	Apr 19	Buy	1.82	10,000	18,200	20,000	Apr 20 07:56 PM
Sukhtian Faisal Ghiath	Director	Apr 19	Buy	1.82	10,000	18,200	20,000	Apr 20 07:55 PM
Evanson Jeff	Chief Commercial Officer	Feb 23	Sale	2.09	8,554	17,861	1,141,930	Feb 25 08:52 PM
Dagnon Terry	Chief Operating Officer	Feb 23	Sale	2.09	15,900	33,199	1,127,857	Feb 25 08:51 PM
Evanson Jeff	Chief Commercial Officer	Feb 12	Sale	2.55	56,973	145,281	1,150,484	Feb 17 09:14 PM
Dagnon Terry	Chief Operating Officer	Feb 12	Sale	2.55	63,700	162,435	1,143,757	Feb 17 09:13 PM
Syntone Ventures LLC	10% Owner	Feb 03	Buy	1.00	3,000,000	3,000,000	19,823,045	Feb 04 08:54 PM
Sukhtian Ghiath M.	Director	Feb 02	Buy	1.00	8,360,000	8,360,000	10,820,630	Feb 02 05:32 PM
Haddadin Yezan Munther	Director	Sep 22	Buy	0.72	10,000	7,245	10,000	Sep 22 05:14 PM
Sukhtian Faisal Ghiath	Director	Sep 17	Buy	0.67	10,000	6,731	10,000	Sep 17 07:18 PM
THURMAN RANDY H	Director	Sep 14	Buy	0.62	10,000	6,200	11,875	Sep 15 06:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience